▶ 調査レポート

緑内障治療の世界市場:動向・シェア・規模・予測

• 英文タイトル:Glaucoma Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

IMARCが調査・発行した産業分析レポートです。緑内障治療の世界市場:動向・シェア・規模・予測 / Glaucoma Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027 / MRC-IM30188資料のイメージです。• レポートコード:MRC-IM30188
• 出版社/出版日:IMARC / 2022年10月
• レポート形態:英文、PDF、143ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥349,860 (USD2,499)▷ お問い合わせ
  Enterprisewide¥629,860 (USD4,499)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
IMARC社の調査レポートによると、世界の緑内障治療市場規模は2021年に70億ドルに達しました。今後、2027年には102億ドルになり、2022年から2022年の間に年平均6.52%成長すると予測しています。本調査レポートでは、緑内障治療の世界市場について調査・分析を行い、序論、調査範囲・手法、エグゼクティブサマリー、イントロダクション、薬物クラス別(プロスタグランジン類似体、ベータブロッカー、アルファアドレナリンアゴニスト、併用薬、その他)分析、疾患別(開放隅角緑内障、閉塞隅角緑内障、その他)分析、エンドユーザー別(病院、眼科クリニック、ASC、その他)分析、地域別(北米、アジア、欧州、中南米、中東・アフリカ)分析、SWOT分析(強み・弱み・機会・脅威)、バリューチェーン分析、ファイブフォース分析、価格分析、競争状況などを掲載しています。なお、企業情報には、Aerie Pharmaceuticals Inc., Allergan Plc, Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Inotek Pharmaceuticals Corp., Merck & Co. Inc., Novartis AG, Pfizer Inc., Santen Pharmaceutical Co. Ltd., SIFI S.p.A and Teva Pharmaceutical Industries Ltd.などが含まれています。
・序論
・調査範囲・手法
・エグゼクティブサマリー
・イントロダクション
・世界の緑内障治療市場規模:薬物クラス別
- プロスタグランジン類似体の市場規模
- ベータブロッカーの市場規模
- アルファアドレナリンアゴニストの市場規模
- 併用薬の市場規模
- その他薬物の市場規模
・世界の緑内障治療市場規模:疾患別
- 開放隅角緑内障における市場規模
- 閉塞隅角緑内障における市場規模
- その他疾患における市場規模
・世界の緑内障治療市場規模:エンドユーザー別
- 病院における市場規模
- 眼科クリニックにおける市場規模
- ASCにおける市場規模
- その他エンドユーザーにおける市場規模
・世界の緑内障治療市場規模:地域別
- 北米の緑内障治療市場規模
- アジアの緑内障治療市場規模
- 欧州の緑内障治療市場規模
- 中南米の緑内障治療市場規模
- 中東・アフリカの緑内障治療市場規模
・SWOT分析(強み・弱み・機会・脅威)
・バリューチェーン分析
・ファイブフォース分析
・価格分析
・競争状況

The global glaucoma therapeutics market size reached US$ 7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 10.2 Billion by 2027, exhibiting a growth rate (CAGR) of 6.52% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Glaucoma therapeutics refers to various treatment alternatives for primary open-angle (POA) and primary angle-closure (PAC) glaucoma. The disease is characterized by structural changes in the optic nerves that usually lead to visual loss and blindness. The treatment for glaucoma can be initiated through topical eye drops, which majorly consist of beta-blockers, prostaglandin analogs, cholinergic, carbonic anhydrase inhibitors and alpha-adrenergic agonists. These eye drops minimize the production of fluid in the eyes, thereby reducing the intraocular pressure (IOP). This can be followed by traditional or laser surgical procedures or a combination of both, which use products such as implantable extended-release devices, polymer-based contact lenses, drug-eluting punctal plugs, microneedle-injection devices and micro-dosing technologies.

The increasing prevalence of glaucoma across the globe represents one of the key factors driving the growth of the market. Glaucoma is highly prevalent in patients with diabetes and other eye disorders, such as age-related macular degeneration (AMD), cataract and dry eye. In line with this, the rising geriatric population, which is more susceptible to such ailments, is creating a positive outlook for the market growth. Furthermore, increasing health consciousness among the masses and rising preference for laser glaucoma surgery is also driving the market growth. Additionally, the development of innovative combination dugs is acting as another growth-inducing factor. Pharmaceutical manufacturers are creating anti-glaucoma drugs and prostaglandin analogs combined with two or more drugs to control the elevated levels of IOP. Other factors, including the advent of advanced glaucoma diagnostic techniques, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global glaucoma therapeutics market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug class, indication and end user.

Breakup by Drug Class:

Prostaglandin Analogs
Beta Blockers
Alpha Adrenergic Agonists
Carbonic Anhydrase Inhibitors
Combination Drugs
Others

Breakup by Indication:

Open Angle Glaucoma
Angle Closure Glaucoma
Others

Breakup by End User:

Hospitals
Ophthalmic Clinics
Ambulatory Surgery Centers
Others

Breakup by Region:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Aerie Pharmaceuticals Inc., Allergan Plc, Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Inotek Pharmaceuticals Corp., Merck & Co. Inc., Novartis AG, Pfizer Inc., Santen Pharmaceutical Co. Ltd., SIFI S.p.A and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:
How has the global glaucoma therapeutics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global glaucoma therapeutics market?
What are the key regional markets?
What is the breakup of the market based on the drug class?
What is the breakup of the market based on the indication?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global glaucoma therapeutics market and who are the key players?
What is the degree of competition in the industry?

レポート目次

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Glaucoma Therapeutics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Class
6.1 Prostaglandin Analogs
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Beta Blockers
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Alpha Adrenergic Agonists
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Carbonic Anhydrase Inhibitors
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Combination Drugs
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast
7 Market Breakup by Indication
7.1 Open Angle Glaucoma
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Angle Closure Glaucoma
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Others
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by End User
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Ophthalmic Clinics
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Ambulatory Surgery Centers
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Aerie Pharmaceuticals Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.2 Allergan Plc
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 SWOT Analysis
14.3.4 Inotek Pharmaceuticals Corp.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5 Merck & Co. Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Novartis AG
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Pfizer Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Santen Pharmaceutical Co. Ltd.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 SIFI S.p.A
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.10 Teva Pharmaceutical Industries Ltd.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis

Figure 1: Global: Glaucoma Therapeutics Market: Major Drivers and Challenges
Figure 2: Global: Glaucoma Therapeutics Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Glaucoma Therapeutics Market: Breakup by Drug Class (in %), 2021
Figure 4: Global: Glaucoma Therapeutics Market: Breakup by Indication (in %), 2021
Figure 5: Global: Glaucoma Therapeutics Market: Breakup by End User (in %), 2021
Figure 6: Global: Glaucoma Therapeutics Market: Breakup by Region (in %), 2021
Figure 7: Global: Glaucoma Therapeutics Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 8: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market: Sales Value (in Million US$), 2016 & 2021
Figure 9: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 10: Global: Glaucoma Therapeutics (Beta Blockers) Market: Sales Value (in Million US$), 2016 & 2021
Figure 11: Global: Glaucoma Therapeutics (Beta Blockers) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 12: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 14: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 16: Global: Glaucoma Therapeutics (Combination Drugs) Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: Global: Glaucoma Therapeutics (Combination Drugs) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 18: Global: Glaucoma Therapeutics (Other Drug Classes) Market: Sales Value (in Million US$), 2016 & 2021
Figure 19: Global: Glaucoma Therapeutics (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 20: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 24: Global: Glaucoma Therapeutics (Other Indications) Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: Global: Glaucoma Therapeutics (Other Indications) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 26: Global: Glaucoma Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2016 & 2021
Figure 27: Global: Glaucoma Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 30: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market: Sales Value (in Million US$), 2016 & 2021
Figure 31: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 32: Global: Glaucoma Therapeutics (Other End Users) Market: Sales Value (in Million US$), 2016 & 2021
Figure 33: Global: Glaucoma Therapeutics (Other End Users) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 34: North America: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 35: North America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 36: United States: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 37: United States: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 38: Canada: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 39: Canada: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 40: Asia Pacific: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 41: Asia Pacific: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 42: China: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 43: China: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 44: Japan: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 45: Japan: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 46: India: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 47: India: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 48: South Korea: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 49: South Korea: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 50: Australia: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 51: Australia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 52: Indonesia: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 53: Indonesia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 54: Others: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 55: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 56: Europe: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 57: Europe: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 58: Germany: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 59: Germany: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 60: France: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 61: France: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 62: United Kingdom: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 63: United Kingdom: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 64: Italy: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 65: Italy: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 66: Spain: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 67: Spain: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 68: Russia: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 69: Russia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 70: Others: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 71: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 72: Latin America: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 73: Latin America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 74: Brazil: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 75: Brazil: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 76: Mexico: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 77: Mexico: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 78: Others: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 79: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 80: Middle East and Africa: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2016 & 2021
Figure 81: Middle East and Africa: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 82: Global: Glaucoma Therapeutics Industry: SWOT Analysis
Figure 83: Global: Glaucoma Therapeutics Industry: Value Chain Analysis
Figure 84: Global: Glaucoma Therapeutics Industry: Porter’s Five Forces Analysis